{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.99","upperLimit":"6.74","value":"4.37"},{"groupId":"OG001","lowerLimit":"4.11","upperLimit":"10.61","value":"7.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"OS defined as the time between the start of treatment and death from any cause for participants treated with ADCT-301 as monotherapy and for participants treated with ADCT-301 in combination with pembrolizumab.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20, 30, 45, 60, 80, 100, 125 and 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"ADCT-301 Monotherapy"},{"description":"Participants received 20, 30, 45, 60, 80, 100, 125 and 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG001","title":"ADCT-301 Combination Therapy"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set: The Efficacy analysis set consisted of all participants who received at least 1 dose of study drug, had valid Baseline disease assessment(s), and at least one valid post-Baseline disease assessment. The monotherapy arms and combination arms were pooled as pre-specified in protocol section 3.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}